Great — here’s a concise, research-ready brief for the Cholera Vaccine Market, with company references + the best public values I could find, followed by the requested sections. I cite the most important sources for the load-bearing facts so you can follow up.

This versatile research report is presenting crucial details on market relevant information, harping on ample minute details encompassing a multi-dimensional market that collectively maneuver growth in the global Cholera Vaccine market.

This holistic report presented by the report is also determined to cater to all the market specific information and a take on business analysis and key growth steering best industry practices that optimize million-dollar opportunities amidst staggering competition in Cholera Vaccine market.

Read complete report at: https://www.thebrainyinsights.com/report/cholera-vaccine-market-13727

Company references (with values / public figures)

• EuBiologics Co., Ltd. (South Korea) — largest current supplier of WHO-prequalified oral cholera vaccine (Euvichol / Euvichol-Plus). Public statements: >80% market share of outbreak supply and production capacity reported up to ~50 million doses/year (company / Gavi interviews). 

• Valneva SE (France) — manufacturer of DUKORAL® (oral cholera & ETEC vaccine for travelers). DUKORAL® sales: €32.3M in 2024 (Valneva full-year 2024 results). DUKORAL is an important travel-market product and government/DoD purchaser. 

• Bharat Biotech (India) — new entrant with Hillchol (oral cholera vaccine) — completed Phase III and reported capacity plans of up to 200 million doses/year (initial 45 million/year start; investments ~USD 100M cited) to help ease global shortages; pursuing WHO prequalification to supply UNICEF/Gavi. 

• Shantha Biotechnics / Sanofi (India / Sanofi group) — historical supplier of Shanchol™ (widely used in mass campaigns). Several sources report Sanofi/Shantha significantly curtailed or withdrew production (decision by end-2022) which contributed to recent global shortages; however you’ll also see reporting about WHO prequalification items relating to Shanchol in 2025 (market/press items differ — see notes below).

• Other manufacturers / historically relevant: Vabiotech (Vietnam), Valneva (original Dukoral developer), and others (several local suppliers and manufacturers with smaller/travel-market footprints). VAXCHORA (live oral vaccine indicated for travellers) is marketed for travel medicine (product site). Exact cholera-segment revenues are often grouped in larger product lines.

Important sourcing note: cholera vaccine commercial data are fragmented. Many doses are purchased through Gavi/UNICEF stockpiles and manufacturers report production capacity rather than neat “vaccine revenue” lines. Where companies report sales (e.g., Valneva for Dukoral), I cited those numbers.

Market size & recent development (short)

• Representative market estimates vary by research firm because of differing definitions (only outbreak supply vs. travel vaccines vs. combined). Examples:

  • Grand View Research: USD 93.9M (2024) → projected USD 163.4M by 2030 (CAGR ≈10%). 

  • Other firms show similar magnitude ranges (many reports ~USD 90–105M in 2024 with mid-to-high single-digit to low-double-digit CAGRs). (See Market.US / NovaOne / TowardsHealthcare summaries).

• Recent critical development: global outbreaks in 2023–2024 dramatically depleted the global OCV (oral cholera vaccine) stockpile, driving emergency demand and urgent scaling plans by EuBiologics and new entrants (e.g., Bharat Biotech/Hillchol). Reports highlight single-supplier strain (EuBiologics) after Shantha/Sanofi stepped back — prompting Gavi/UNICEF and manufacturers to accelerate capacity.

Drivers

1. Large / recurrent outbreaks (conflict zones, climate-driven flooding, poor WASH) increasing emergency vaccine demand.

2. Gavi/UNICEF & WHO procurement programs for reactive and preventive mass campaigns — major demand channel.

3. New manufacturer capacity (Bharat Biotech, EuBiologics expansion) and investments to reduce single-supplier risk.

4. Traveler vaccination demand (Dukoral, Vaxchora) sustaining a steady market segment in high-income countries.

Restraints

• Supplier concentration & stockpile depletion — when one or two suppliers dominate, shortages occur rapidly.

• Low commercial profitability for routine supply to low-income countries — much procurement relies on donor funding (Gavi/UNICEF) rather than commercial markets. 

• Regulatory / PQ timelines — WHO prequalification requirement for UNICEF procurement creates lead times before new manufacturers can scale to global tenders.

Regional segmentation analysis

• Africa & South Asia — largest demand in outbreak and preventive campaign settings; Gavi/UNICEF procurements focus here. Recent surge in African outbreaks drove emergency demand in 2024.

• Asia-Pacific — manufacturing base (EuBiologics Korea; Bharat Biotech and Shantha in India; Vabiotech in Vietnam) — strong production footprint and growing domestic/regional supply.

• North America & Europe — travel-market customers (Dukoral, Vaxchora), smaller public-health stockpiles; procurement often at national travel-medicine level. 

Emerging trends

• New entrants scaling (Bharat Biotech / Hillchol) to diversify supply and reduce stockpile risk.

• Dose-sparing / single-dose strategies in emergency campaigns to stretch stockpiles (operational research). 

• Manufacturers increasing capacity with donor prepayments (Gavi/UNICEF support) and local manufacturing investments.

Top use cases

1. Mass reactive campaigns during outbreaks (primary current driver).

2. Preventive (pre-emptive) vaccination in high-risk settings (endemic areas, refugee camps).

3. Travel medicine (individual vaccination for travelers to endemic areas — Dukoral, Vaxchora).

Major challenges

• Fragile supplier base (stockouts when one producer scales down).

• Funding & procurement cycles — donor budgets and emergency financing shape availability.

• PQ / regulatory bottlenecks slow time-to-market for new manufacturers aiming to supply UNICEF/Gavi.

Attractive opportunities

• Bharat Biotech scale-up — large dose capacity could relieve global shortages if WHO prequalification is achieved.

• Contract manufacturing and regional fill/finish in Africa/Asia to shorten supply chains.

• Public-private funding models (advance purchase commitments / prepayments by Gavi/UNICEF) to de-risk manufacturer investments.

Key factors of market expansion

• Sustained donor funding (Gavi/UNICEF/WHO) to underpin large-volume procurements.

• More WHO-PQ manufacturers (diversification) — reduces single-supplier risk and enables predictable supply.

• Higher global cholera burden (conflict/climate impacts) raising urgency for preventive campaigns.

Quick takeaways / actionable options

• If you want a vendor table: I can assemble a CSV/Excel with manufacturers (EuBiologics, Valneva, Bharat Biotech, Shantha/Sanofi history, Vabiotech, others), reported dose capacities, any public revenue lines (e.g., Valneva Dukoral €32.3M 2024), WHO-PQ status and source links for each cell.

• If you want a short market-share model: I can estimate shares using reported production capacities (EuBiologics ~50M, Bharat Biotech up to 200M planned vs. historical demand ~100M/yr estimates) and show confidence bands & assumptions.

Sources (representative / for follow-up)

Key sources used above (clickable in the UI where available): Grand View Research market report; CDC/WHO cholera vaccine pages; EuBiologics corporate / Gavi interviews; Valneva FY-2024 results (Dukoral sales); Reuters / Times of India coverage of Bharat Biotech Hillchol; investigative & news pieces on global stockpile depletion.

Want me to build the vendor spreadsheet now (CSV / Excel) with the columns: Manufacturer | Product(s) | HQ | WHO-PQ (Y/N) | Reported capacity / doses | Public revenue (if any) | Source link ? If yes, I’ll assemble it and attach the file.